Romiplostim: The Thrombopoietin Receptor Agonist for ITP
What is Romiplostim?
Romiplostim is a thrombopoietin receptor agonist used in chronic immune thrombocytopenia (ITP) patients who have insufficient response to corticosteroids and immunoglobulins. It stimulates the production of platelets in the bone marrow, helping to manage bleeding and bruising associated with low platelet count.
How Romiplostim Works
Romiplostim binds to the thrombopoietin receptor on megakaryocytes, the cells that produce platelets in the bone marrow. This stimulation promotes platelet production, increasing platelet counts and improving bleeding tendencies in ITP patients.
When to Use Romiplostim
● Chronic Immune Thrombocytopenia (ITP): Romiplostim is prescribed for chronic ITP in patients who do not respond to steroids or splenectomy.
● Low Platelet Counts: It is used to raise platelet counts and reduce bleeding risk in individuals with severe thrombocytopenia.
Dosage
● Adult Dose for ITP: The typical starting dose is 1 mcg/kg once a week, which may be adjusted based on the patient’s platelet count. Maximum dose is 10 mcg/kg/week.
● Pediatric dosage: The typical starting dose is 1 mcg/kg once a week, which may be adjusted based on the patient’s platelet count. Maximum dose is 10 mcg/kg/week.
Common brands: Romy
Side Effects
● Common Effects: Fatigue, joint pain, dizziness, and headache.
● Serious Adverse Effects: Bone marrow fibrosis, thromboembolic events, and severe allergic reactions.
